Press release
Cough in Idiopathic Pulmonary Fibrosis Market Analysis: Epidemiology, Therapies, Companies, DelveInsight | NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma
The Cough in Idiopathic Pulmonary Fibrosis Market is projected to witness consistent growth throughout the forecast period (2023-2034). The Cough in Idiopathic Pulmonary Fibrosis Market Size in the 7MM is expected to increase, driven by the launch of emerging therapies.The Cough in Idiopathic Pulmonary Fibrosis (IPF) market is expected to grow in the coming years, driven by therapies such as Orvepitant Maleate, Haduvio (nalbuphine ER), and other emerging treatments.
DelveInsight has released a detailed report titled "Cough in Idiopathic Pulmonary Fibrosis - Market Insights, Epidemiology, and Market Forecast 2034," providing a comprehensive analysis of IPF-related cough. The report covers historical and projected epidemiology as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Key companies active in this market include NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, and Emphycorp.
Discover about the Cough in Idiopathic Pulmonary Fibrosis market report [https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Some of the key facts of the Cough in Idiopathic Pulmonary Fibrosis Market Report:
*
The Cough in Idiopathic Pulmonary Fibrosis (IPF) market is projected to experience steady growth from 2023 to 2034, largely driven by the emergence of new therapeutic options. According to DelveInsight, the United States accounted for roughly 51% of all diagnosed prevalent cases of cough in IPF across the seven major markets (7MM). In 2022, the EU4 and the UK together reported about 55,000 diagnosed cases.
*
In 2022, the 7MM market primarily consisted of neuromodulators, corticosteroids, and other immunomodulators, generating approximately USD 154 million in revenue. Looking forward, the market is expected to expand with the launch of novel therapies such as Orvepitant Maleate and Haduvio (nalbuphine ER), which aim to improve treatment outcomes for IPF-related cough.
*
DelveInsight estimates indicate that there were around 148,000 diagnosed prevalent cases of IPF-associated cough across the 7MM in 2022, with numbers anticipated to rise throughout the forecast period. In the U.S. alone, about 95,000 individuals were diagnosed with IPF in 2022, and this figure is expected to grow at a compound annual growth rate (CAGR) through 2034.
*
Haduvio (oral nalbuphine ER) demonstrated a ~60% reduction in 24-hour cough frequency in IPF patients, supported by strong safety data. Trevi Therapeutics plans to request an End-of-Phase 2 meeting with the FDA and initiate a Phase 3 program in 2026.
*
Key companies active in this market, including NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others, are actively developing new therapies to enhance the treatment landscape for cough in IPF. Promising candidates include Orvepitant Maleate, Haduvio (nalbuphine ER), among others.
Cough in Idiopathic Pulmonary Fibrosis Overview
Chronic cough is a prevalent and often early symptom of idiopathic pulmonary fibrosis (IPF), having a profound impact on patients' quality of life. It is associated with increased psychological distress, such as depression and anxiety, greater physical limitations, and worsening disease severity.
The mechanisms behind cough in IPF are complex and not fully understood. Current research indicates a multifactorial origin, involving impaired mucus production and clearance, structural alterations in lung tissue, and enhanced cough reflex sensitivity. These factors together contribute to the persistence and intensity of the cough, which is closely linked to health deterioration and disease progression in IPF patients.
Cough in Idiopathic Pulmonary Fibrosis Market Outlook
Cough is a major and debilitating symptom of idiopathic pulmonary fibrosis (IPF), substantially reducing patients' quality of life and underscoring the need for effective, symptom-specific therapies. While treatments for IPF exist, none are currently approved to specifically address chronic cough associated with the disease.
Current management strategies focus either on suppressing the cough reflex or targeting the underlying IPF pathology. However, commonly used agents like dextromethorphan and opioids provide limited relief and may cause unwanted systemic side effects. Approved IPF therapies, including pirfenidone and nintedanib, primarily slow disease progression but offer minimal impact on cough symptoms.
There is increasing focus on developing targeted treatments for IPF-related cough. Investigational approaches using neuromodulators, immunomodulators, and behavioral interventions show promise, though further clinical evidence is required to confirm their effectiveness.
In 2022, the cough in IPF therapeutic market across the 7MM was valued at approximately USD 154 million and is expected to grow considerably with the anticipated approval of promising candidates such as Orvepitant Maleate and Haduvio (nalbuphine ER).
Discover how the Cough in Idiopathic Pulmonary Fibrosis market is rising in the coming years @ https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs
*
Orvepitant Maleate: NeRRe Therapeutics
*
Haduvio (nalbuphine ER): Trevi Therapeutics
Scope of the Cough in Idiopathic Pulmonary Fibrosis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, Cellular Sciences, Emphycorp, and others
*
Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), and others.
*
Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
*
Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Cough in Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Cough in Idiopathic Pulmonary Fibrosis Market Access and Reimbursement
To know what's more in our Cough in Idiopathic Pulmonary Fibrosis report, visit https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Cough in Idiopathic Pulmonary Fibrosis Market Report:
*
The Cough in Idiopathic Pulmonary Fibrosis market report covers a descriptive overview and comprehensive insight of the Cough in Idiopathic Pulmonary Fibrosis Epidemiology and Cough in Idiopathic Pulmonary Fibrosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
*
The Cough in Idiopathic Pulmonary Fibrosis market report provides insights into the current and emerging therapies.
*
The Cough in Idiopathic Pulmonary Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Cough in Idiopathic Pulmonary Fibrosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cough in Idiopathic Pulmonary Fibrosis market.
Got queries? Click here to know more about the Cough in Idiopathic Pulmonary Fibrosis market Landscape [https://www.delveinsight.com/sample-request/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cough in Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance
5. Cough in Idiopathic Pulmonary Fibrosis Market Overview at a Glance
6. Cough in Idiopathic Pulmonary Fibrosis Disease Background and Overview
7. Cough in Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Cough in Idiopathic Pulmonary Fibrosis
9. Cough in Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices
10. Unmet Needs
11. Cough in Idiopathic Pulmonary Fibrosis Emerging Therapies
12. Cough in Idiopathic Pulmonary Fibrosis Market Outlook
13. Country-Wise Cough in Idiopathic Pulmonary Fibrosis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cough in Idiopathic Pulmonary Fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Cough in Idiopathic Pulmonary Fibrosis Market Outlook 2034 [https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Cough in Idiopathic Pulmonary Fibrosis Pipeline Insights, DelveInsight
"Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis market. A detailed picture of the Cough in Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Cough in Idiopathic Pulmonary Fibrosis treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cough-in-idiopathic-pulmonary-fibrosis-market-analysis-epidemiology-therapies-companies-delveinsight-nerre-therapeutics-trevi-therapeutics-algernon-pharmaceuticals-seyltx-inc-melius-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cough in Idiopathic Pulmonary Fibrosis Market Analysis: Epidemiology, Therapies, Companies, DelveInsight | NeRRe Therapeutics, Trevi Therapeutics, Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma here
News-ID: 4210393 • Views: …
More Releases from ABNewswire
Injectable Academy Recognized as Top-Rated Botox and Filler Training Provider in …
Recognition highlights the academy's commitment to hands-on, safety-focused education for healthcare professionals in the booming Georgia aesthetic market.
Atlanta, GA - November 17, 2025 - Injectable Academy [https://injectableacademy.com/], a premier provider of aesthetic medical education, today announced it has been recognized as the top-rated Botox Registered and dermal filler training course for healthcare professionals in the Atlanta and Savannah, GA metropolitan area. This distinction is based on consistently superior graduate reviews,…
PhotoScanRestore Unveils Advanced AI Colorization Technology as a Powerful Photo …
United States - PhotoScanRestore today announced the launch of its next-generation AI restoration technology, offering families a powerful and accessible way to photoScanRestore [https://photoscanrestore.com] their historical memories. As more users search for a Photomyne alternative, the company is introducing a modern colorize app designed to transform old black-and-white photographs into vivid, lifelike digital images.
Every family holds treasured black-and-white portraits-images of grandparents, great-grandparents, and ancestors whose stories have faded with time.…
Mhtwyat Sets New Standards for Accuracy as Arabic Users Seek Dependable Informat …
In today's digital world, accessing information is easy, yet finding trustworthy and accurate content remains a challenge for many Arabic-speaking users. mhtwyat.com stands out as one of the most important Arabic platforms offering diverse content covering a wide range of topics, from culture and history to education, health, and entertainment. It has become an indispensable resource for students, researchers, and casual readers alike.
For readers seeking a trusted source of structured…
Guyker Releases New Guide Exploring Guitar Parts Visual Style Sonic Personality
Image: https://www.abnewswire.com/upload/2025/11/5b1d6999dd3fccb4fc408fb6fcd6bcdd.jpg
The world is being dominated by the guitar as one of the most versatile instruments. It generates sound by vibration of strings, which can be amplified or played acoustically. Its design is limitlessly creative, whether it is rock, blues, classical, or folk music. Understanding the functioning of a guitar helps players achieve better tuning, proficiency, and control.
The role of each component of a guitar is different in creating sound…
More Releases for Cough
Dog's Cough Intensifies Due to Temperature Difference, Trusted Dog Cough Medicin …
Image: https://www.getnews.info/uploads/e50cc9d317e270f5e3e669a0339f0b84.jpg
During periods of significant temperature fluctuations, not only humans but also many dogs are prone to experiencing coughing symptoms. Differences between daytime and nighttime temperatures, dry weather, and frequent transitions between indoor and outdoor environments can directly affect the bronchial health of dogs, making them more susceptible to respiratory problems. In particular, sudden changes in weather can make a dog's respiratory system sensitive, resulting in noticeable coughing symptoms.
Coughing in…
Cough Care Advance launches Cough Care Advance, an innovative, kid-friendly coug …
Cough Care Advance is introducing an innovative, kid-friendly cough remedy that provides safe, natural, and long-lasting relief.
Parents know how difficult it can be when children are battling a stubborn cough. Whether it's keeping them up at night or disrupting their day at school, finding an effective and gentle solution is a top priority. That's why Cough Care Advance is introducing an innovative, kid-friendly cough remedy that provides safe, natural, and…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Refractory Chronic Cough Therapeutics Market - Pioneering Solutions for Persiste …
Newark, New Castle, USA - new report, titled Refractory Chronic Cough Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Refractory Chronic Cough Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Refractory Chronic Cough Therapeutics market. The report offers…
Cough Systems Market
Global cough systems market size is expected to be worth roughly USD 192.8 million by 2030, growing at a CAGR of more than 8.6% during the projected timeframe of 2022-2030, according to Ameco Research
Cough systems are appliances that assist to cleanse the lungs of excessive cough output by changing the flow patterns, which enhances the airway patency and helps to establish and promote alveolar growth. Excessive coughing produces severe lung…
Global Cough Syrup Market Size, Cough Syrup Market Share, Cough Syrup Market Gro …
The Global "Cough Syrup Market" 2022 research report presents an in-depth analysis of the Cough Syrup Market size, growth, share, segments, manufacturers, and forecast, competition landscape and growth opportunity. The research's goal is to provide market data and strategic insights to help decision-makers to make educated investment decisions while also identifying potential gaps and development possibilities.We also analysed the impact of COVID-19 (Corona Virus) on the product industry chain based…
